Alsterpaullone, Avotaciclib, Fostamatinib, and Naringin demonstrated acceptable inhibitory effects on both CDK1 and WEE1 proteins, suggesting potential for synergistic control of cancer cell proliferation. Here, CDK1 is linked to cancer.